Sharps Technology Inc. (STSS)

Sharps Technology Inc. (STSS) Healthcare & Pipeline Overview

Sharps Technology Inc. specializes in safety syringe technology, offering the Sharps Provensa syringe designed to minimize waste in vaccine and medication administration. Operating within the medical instruments and supplies sector, the company addresses the critical need for efficient and safe injection solutions in the U.S. market.

What Is the Investment Thesis for STSS?

Sharps Technology Inc. presents a focused investment opportunity within the medical device sector, centered around its Sharps Provensa ultra-low waste syringe. The company's potential lies in capitalizing on the increasing demand for efficient and safe injection solutions, particularly in vaccine administration. A key value driver is the potential for expanded market penetration within the U.S. healthcare system. However, the company's current negative profit margin of -11724.3% raises concerns about its financial sustainability. Successful scaling of production and distribution, along with effective cost management, are critical for achieving profitability. Investors should closely monitor the company's ability to secure contracts, manage operational expenses, and demonstrate revenue growth.

Based on FMP financials and quantitative analysis

STSS Key Highlights

• Market capitalization of $52.27M indicates a small-cap company with potential for growth but also higher volatility.
• Gross margin of 57.1% suggests a strong ability to control production costs relative to revenue.
• Negative profit margin of -11724.3% highlights significant challenges in achieving profitability.
• Beta of 2.07 indicates higher volatility compared to the overall market.
• Focus on Sharps Provensa, an ultra-low waste space syringe, positions the company to capitalize on the growing demand for efficient medication delivery systems.

Who Are STSS's Competitors?

STSS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STSS's Key Strengths?

• Innovative Sharps Provensa syringe technology.
• Focus on reducing medication waste.
• Potential for improved patient safety.
• Strong gross margin.

What Are STSS's Weaknesses?

• Negative profit margin.
• Limited product portfolio.
• Concentration on the U.S. market.
• Small market capitalization.

What Could Drive STSS Stock Higher?

• Potential FDA approval for new syringe applications.
• Expansion of distribution network in the United States.
• Increasing adoption of Sharps Provensa by vaccine manufacturers.

What Are the Key Risks for STSS?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $1.4M recently.
• Competition from established medical device companies.
• Regulatory hurdles and compliance requirements.
• Negative profit margin and financial sustainability concerns.
• Product liability claims.

What Are the Growth Opportunities for STSS?

• Expansion of Sharps Provensa adoption within vaccine administration: The increasing global focus on vaccination programs presents a significant growth opportunity for Sharps Technology. By targeting vaccine manufacturers and healthcare providers, the company can drive adoption of its ultra-low waste syringe, reducing vaccine wastage and improving overall efficiency. The global vaccines market is projected to reach $90 billion by 2028, offering a substantial addressable market for Sharps Technology's innovative syringe.
• Strategic partnerships with pharmaceutical companies: Collaborating with pharmaceutical companies to integrate Sharps Provensa into their drug delivery systems can accelerate market penetration and enhance brand recognition. By partnering with companies developing injectable medications, Sharps Technology can ensure its syringe is the preferred choice for administering these drugs. This strategy can lead to long-term contracts and recurring revenue streams, solidifying the company's position in the market.
• Geographic expansion beyond the United States: While currently focused on the U.S. market, Sharps Technology can explore opportunities to expand its reach into international markets. Countries with developing healthcare infrastructure and a growing demand for safe injection practices represent attractive targets for expansion. Adapting the Sharps Provensa syringe to meet local regulatory requirements and cultural preferences will be crucial for successful international expansion.
• Development of new syringe technologies and applications: Investing in research and development to create new syringe technologies and expand the applications of Sharps Provensa can drive long-term growth. Exploring opportunities in areas such as insulin delivery, cosmetic injections, and veterinary medicine can diversify the company's product portfolio and reduce its reliance on a single market segment. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry.
• Leveraging government initiatives and funding programs: Government initiatives aimed at improving healthcare efficiency and reducing medical waste can provide significant growth opportunities for Sharps Technology. By actively participating in these programs and seeking government funding, the company can accelerate the adoption of its Sharps Provensa syringe and contribute to broader healthcare goals. Staying informed about relevant government policies and regulations is crucial for capitalizing on these opportunities.

What Opportunities Does STSS Have?

• Expansion into international markets.
• Partnerships with pharmaceutical companies.
• Development of new syringe technologies.
• Leveraging government healthcare initiatives.

What Threats Does STSS Face?

• Competition from established medical device companies.
• Regulatory hurdles and compliance requirements.
• Potential for product liability claims.
• Fluctuations in healthcare spending.

What Are STSS's Competitive Advantages?

• Proprietary Sharps Provensa technology with ultra-low waste design.
• Focus on safety and efficiency in medication delivery.
• Established relationships with healthcare providers in the United States.
• Potential for patents and intellectual property protection.

What Does STSS Do?

Sharps Technology Inc., established in 2017 and headquartered in Melville, New York, is a medical device company dedicated to researching, designing, developing, manufacturing, distributing, and selling safety syringe products. The company's flagship product, Sharps Provensa, is an ultra-low waste space syringe engineered to optimize the administration of vaccines and injectable medications. This innovative syringe aims to reduce medication waste, improve dosage accuracy, and enhance safety for healthcare providers and patients. Sharps Technology focuses on the United States market, catering to healthcare facilities, pharmacies, and government agencies seeking advanced injection solutions. The company's commitment to innovation and safety positions it as a key player in the evolving medical device landscape, addressing the growing demand for efficient and safe drug delivery systems.

What Products and Services Does STSS Offer?

• Researches and designs safety syringe products.
• Develops innovative syringe technologies to minimize waste.
• Manufactures safety syringes for vaccine and medication administration.
• Distributes syringes to healthcare facilities and pharmacies.
• Sells safety syringe products in the United States.
• Offers the Sharps Provensa ultra-low waste space syringe.

How Does STSS Make Money?

• Direct sales to healthcare providers and pharmacies.
• Distribution agreements with medical supply companies.
• Partnerships with pharmaceutical companies for drug delivery systems.
• Government contracts for vaccine administration programs.

What Industry Does STSS Operate In?

Sharps Technology Inc. operates in the medical instruments and supplies industry, a sector characterized by continuous innovation and stringent regulatory oversight. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Competition is intense, with established players and emerging companies vying for market share. Sharps Technology's focus on safety syringe technology aligns with the industry's emphasis on patient safety and efficient healthcare delivery. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and establish strong relationships with healthcare providers.

Who Are STSS's Key Customers?

• Hospitals and clinics.
• Pharmacies and retail drug stores.
• Vaccine manufacturers.
• Government healthcare agencies.

ROE 12%Key Financial Metrics

Return on equity for Sharps Technology Inc. stands at 12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.2%, showing how much profit it generates from its asset base. STSS trades at a trailing price-to-earnings ratio of 1.22, below the Healthcare sector average of ~23x. Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 74.0%, the inverse of the P/E and a quick read on earnings relative to price.

How Sharps Technology Inc. Is Valued

Sharps Technology Inc. carries a market capitalization of $52.27M, placing it in the micro-cap category. Relative to its peer group, STSS's quantitative score of 45/100 is below the peer average of 62/100.

F-Score 3/9Financial Health

Sharps Technology Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.60 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Sharps Technology Inc. revenue of about $72.4M for fiscal 2026, with EPS near $0.00.

Net sellingInsider Activity

Over the past six months, Sharps Technology Inc. insiders filed 9 SEC Form 4 transactions — 8 sales and 1 purchases. On net that is roughly 722K shares disposed (about $1.4M), a signal worth weighing alongside the fundamentals.

STSS Financials

STSS Latest News

STSS Analyst Consensus

STSS MoonshotScore

Sharps Technology Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources